Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Point-of-Care Molecular Diagnostics Market analysis

The UK Point-of-Care Molecular Diagnostics Market was valued at $271.5 Million in 2025 and projected to reach to $468 Million by 2030, representing a compound annual growth rate of 11.5%. The UK point-of-care molecular diagnostics market is positioned for sustained growth through 2030, driven by NHS modernisation initiatives and the shift towards decentralised testing.

UK Point-of-Care Molecular Diagnostics Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Point-of-Care Molecular Diagnostics Market Trends and Insights

  • The UK market is driven by increasing demand for rapid diagnostic solutions in primary care settings, urgent care centres, and community health facilities.
  • The UK's advanced healthcare infrastructure and emphasis on early disease detection are accelerating adoption of point-of-care molecular testing platforms. The UK market benefits from strong regulatory support and NHS integration initiatives that prioritize accessible diagnostics.
  • Between 2025 and 2030, the UK is expected to see significant investment in decentralized testing technologies, particularly for infectious disease screening and chronic disease management.
  • The UK's 11.5% compound annual growth rate outpaces the global average, reflecting the region's commitment to modernizing diagnostic capabilities and reducing laboratory turnaround times..

Key Market Statistics

  • CAGR (2025-2030) 11.5% CAGR
  • Market Size, 2025 ~USD 271.5 Million
  • Forecast, 2030 ~USD 468 Million
  • Country UK

UK Point-of-Care Molecular Diagnostics Market Overview

Market Valuation Growth :

The UK point-of-care molecular diagnostics market is valued at £271.5 million in 2025, with a projected expansion to £468 million by 2030, representing a robust 11.5% CAGR.

Primary Care Integration :

Rapid diagnostic solutions are increasingly being adopted across UK primary care settings, urgent care centres, and community health facilities, driven by NHS efficiency initiatives and patient demand for faster results.

Advanced Healthcare Infrastructure :

The UK's well-established healthcare infrastructure and emphasis on early disease detection create a favourable environment for point-of-care molecular diagnostics adoption and innovation.

Outpacing Global Growth :

The UK market's 11.5% CAGR exceeds the global average of 10.5%, indicating stronger regional demand and accelerated market penetration compared to international markets.

UK Point-of-Care Molecular Diagnostics Market Dynamics

  • Primary care providers are increasingly adopting rapid molecular diagnostics to reduce patient wait times and improve clinical outcomes.
  • The integration of point-of-care testing into community health settings aligns with the UK's long-term healthcare strategy of delivering care closer to patients. Key growth drivers include rising infectious disease prevalence, increased investment in diagnostic infrastructure, and growing awareness of rapid testing benefits among healthcare professionals.
  • Regulatory support from the MHRA and emphasis on antimicrobial stewardship further accelerate market expansion.
  • By 2030, point-of-care molecular diagnostics are expected to become standard practice across UK primary and urgent care settings, with significant opportunities for innovative diagnostic solutions..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • The UK point-of-care molecular diagnostics market is valued at £271.5 million in 2025 and will reach £468 million by 2030, representing a 11.5% CAGR.
      • The UK market growth is driven by NHS digitalization initiatives and increased adoption of rapid testing in primary and urgent care settings.
      • The UK's regulatory environment and healthcare infrastructure position it as a leader in point-of-care molecular diagnostics adoption across Europe.
      • The UK market is expected to see accelerated investment in decentralized testing technologies for infectious diseases and chronic disease management through 2030.

      Point-of-Care Molecular Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SEPSIS (Disease Type)
      Forecast Period 2025-2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment RT-PCR (Technology)
      Market Size Base Year (Billions) ~USD 4.3 (2025)
      Revenue Forecast (Billions) ~USD 7.09 (2030)
      Segments Covered Product & Service, Technology, Sample Type, Application, End User, Disease Type

      UK Point-of-Care Molecular Diagnostics Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product & Service

      • Assays & Kits
      • Instruments & Analyzers
      • Software & Services

      By Technology

      • Inaat
      • Other Technologies
      • Rt-Pcr

      By Sample Type

      • Blood Samples
      • Other Sample Types
      • Urine Samples

      By Application

      • Cancer
      • Gastrointestinal Disorders
      • Hepatitis
      • Hospital-Acquired Infections
      • Other Applications
      • Respiratory Diseases
      • Sexually Transmitted Diseases

      By End User

      • Hospitals
      • Other End Users
      • Physicians' Offices/Clinics
      • Research Institutes

      By Disease Type

      • Gastroenteritis
      • Meningoencephalitis
      • Other Diseases
      • Sepsis

      UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      HOSPITALS104.7113.3123.6136.1151.6170.5193.4221.712.4
      OTHER END USERS30.932.434.236.539.342.84752.28.8
      PHYSICIANS' OFFICES/CLINICS88.795.4103.4113.2125.2139.9157.4179.111.6
      RESEARCH INSTITUTES9.59.910.310.911.712.613.715.17.9
      TOTAL233.8251271.5296.7327.8365.8411.646811.5

      Target Audience

      • Diagnostic Device Manufacturers : Manufacturers need UK-specific market data to develop localised product strategies, understand NHS procurement requirements, and identify opportunities in primary care and community settings.
      • Healthcare Investors & PE Firms : Investors require detailed UK market valuations, growth projections, and competitive landscape analysis to evaluate investment opportunities and assess portfolio company performance in the diagnostics sector.
      • NHS & Healthcare Providers : Healthcare organisations need market insights to inform procurement decisions, budget allocation for diagnostic infrastructure, and understanding of emerging testing solutions for patient care improvement.
      • Regulatory & Policy Bodies : Regulatory agencies and health policy makers require market data to inform healthcare strategy, diagnostic standards development, and resource allocation for NHS modernisation initiatives.
      • Distributors & Healthcare Suppliers : Distributors need UK market segmentation data, growth forecasts, and channel-specific insights to optimise inventory, identify high-potential customer segments, and plan sales strategies.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise UK market valuation (£271.5M in 2025) and verified 11.5% CAGR forecast through 2030, enabling accurate business planning and investment decisions specific to the British market.
      • Competitive Positioning Intelligence : Understand UK-specific market dynamics, primary care adoption rates, and regional competitive landscape to identify gaps and opportunities for product differentiation and market entry strategies.
      • NHS & Healthcare Policy Alignment : Access insights on UK healthcare infrastructure integration, NHS modernisation initiatives, and regulatory environment (MHRA) to align product development with national healthcare priorities.
      • Segment & Channel Analysis : Identify high-growth segments within UK primary care, urgent care centres, and community health facilities with detailed adoption patterns and revenue potential by healthcare setting.
      • Strategic Investment Guidance : Make informed investment and partnership decisions with comprehensive UK market forecasts, growth drivers, and emerging opportunities through 2030 for sustainable business expansion.

      Frequently asked questions

      What is the current size of the UK point-of-care molecular diagnostics market?

      The UK point-of-care molecular diagnostics market is valued at £271.5 million in 2025 and is projected to grow to £468 million by 2030.

      What is the growth rate of the UK market?

      The UK point-of-care molecular diagnostics market is growing at a compound annual growth rate (CAGR) of 11.5% from 2025 to 2030.

      What factors are driving growth in the UK market?

      The UK market is driven by NHS integration initiatives, increased demand for rapid diagnostics in primary care, advanced healthcare infrastructure, and emphasis on early disease detection.

      Which applications are most prominent in the UK market?

      The UK market is seeing strong adoption in infectious disease screening, chronic disease management, and urgent care settings where rapid turnaround times are critical.

      How does the UK market compare to global trends?

      The UK's 11.5% CAGR outpaces the global average of 10.5%, reflecting stronger adoption of point-of-care molecular diagnostics and supportive regulatory policies.

      RESEARCH METHODOLOGY

      The study involved estimating activities to determine the current size of the point-of-care molecular diagnostics market. Exhaustive secondary research was done to collect information on the point-of-care molecular diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the point-of-care molecular diagnostics market.

      Secondary Research

      In the secondary research process, various secondary sources, such as annual reports, press releases, and investor presentations of companies; white papers; certified publications; articles by recognized authors; gold-standard & silver-standard websites; regulatory bodies; and databases like D&B Hoovers, Bloomberg Business, and Factiva, were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

      Breakdown of Primaries

      Point-of-Care Molecular Diagnostics Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both bottom-up and top-down approaches were used to estimate and validate the point-of-care molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in tkehe mart. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research.
      • The revenues generated by leading players operating in the point-of-care molecular diagnostics market have been determined through primary and secondary research.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      Point-of-Care Molecular Diagnostics Market

      Data Triangulation

      After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Point-of-care molecular diagnostics includes various portable point-of-care devices and assays used by healthcare professionals to detect and diagnose diseases in humans using different techniques to identify and analyze nucleic acids or proteins at the molecular level.

      Stakeholders

      • Manufacturers and distributors of point-of-care molecular diagnostics products
      • Physicians’ offices
      • Hospitals and clinics
      • Research institutes
      • Point-of-care molecular diagnostics service providers
      • Government associations
      • Venture capitalists and investors

      Report Objectives

      • To define, describe, segment, and forecast the point-of-care molecular diagnostics market by product & service, technology, sample type, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
      • To analyze opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze company developments such as acquisitions, expansions, product launches & approvals, and other developments in the point-of-care molecular diagnostics market
      • To benchmark players within the point-of-care molecular diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

       

      Get the Full Point-of-Care Molecular Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all Point-of-Care Molecular Diagnostics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status